Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,645 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo twice daily Clear all
Completed Phase 2 Interventional Results available

Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization

NCT02589067
View directory record Official record
Conditions
S. Aureus Oropharyngeal Colonization
Interventions
Chlorhexidine gluconate, Saline Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
5 Years to 18 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 1, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)

NCT00322465
View directory record Official record
Conditions
Urethritis
Interventions
Doxycycline, Placebo, Tinidazole, Azithromycin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 45 Years · Male only
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 1, 2026, 9:32 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia

NCT01035671
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
alpha-tocopherolquinone (A0001), placebo
Drug
Lead sponsor
Penwest Pharmaceuticals Co.
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2011 · Synced Oct 1, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease

NCT01001767
View directory record Official record
Conditions
HIV Infections, Heart Disease
Interventions
Lovaza, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Oct 1, 2026, 9:32 AM EDT
Completed Early Phase 1 Interventional Results available

Zinc Effect on Inflammation and Cardiovascular Risk in HIV

NCT05085834
View directory record Official record
Conditions
Inflammation, Cardiovascular Diseases, Zinc Deficiency
Interventions
Zinc Gluconate, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 1, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 1, 2026, 9:32 AM EDT
Active, not recruiting Phase 3 Interventional Results available

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT02257736
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Abiraterone acetate, Prednisone, Placebo
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
46
States / cities
Phoenix, Arizona • La Mesa, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 1, 2026, 9:32 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Allopurinol for Renal Transplant Associated Hypertension in Children

NCT00288171
View directory record Official record
Conditions
Hypertension, Renal Transplant
Interventions
Placebo, Allopurinol
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 1, 2026, 9:32 AM EDT
Terminated Phase 4 Interventional Results available

Albuterol to Improve Respiratory Strength in SCI

NCT02508311
View directory record Official record
Conditions
Spinal Cord Injury, Respiratory Muscle Weakness
Interventions
Oral Albuterol Extended Release, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 1, 2026, 9:32 AM EDT
Active, not recruiting Phase 3 Interventional

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05600777
View directory record Official record
Conditions
Cough, Refractory Chronic Cough
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 80 Years
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
57
States / cities
Foley, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 1, 2026, 9:32 AM EDT
Active, not recruiting Phase 2 Interventional

Glycemic Regulation as Endometriosis Adjunct Treatment

NCT06611501
View directory record Official record
Conditions
Pelvic Pain, Endometriosis
Interventions
Metformin Hydrochloride, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 1, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability

NCT02002819
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
levetiracetam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 1, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

NCT06545500
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg), Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 1, 2026, 9:32 AM EDT
Completed Not applicable Interventional

Effect of Blueberry Consumption on Metabolic Syndrome & DNA Damage

NCT02075307
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance, DNA Damage
Interventions
Blueberry Powder, Placebo
Dietary Supplement
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
30 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 1, 2026, 9:32 AM EDT
Withdrawn Phase 3 Interventional

Glycine and D-Cycloserine in Schizophrenia

NCT00000372
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Glycine, Clozapine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Oct 1, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

Combination Pain Therapy in HIV Neuropathy

NCT00863057
View directory record Official record
Conditions
HIV Infections, Peripheral Neuropathy
Interventions
Duloxetine, Duloxetine placebo, Methadone, Methadone placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Diego, California • Torrance, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 1, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

NCT00950807
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo, GSK573179
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 1, 2026, 9:32 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

NCT00046072
View directory record Official record
Conditions
Sepsis, Shock, Septic, Sepsis Syndrome, Septicemia, Infection
Interventions
E5564
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
17
States / cities
Mobile, Alabama • San Diego, California • Santa Barbara, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2005 · Synced Oct 1, 2026, 9:32 AM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339
View directory record Official record
Conditions
Diabetic Cardiomyopathies
Interventions
AT-001, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
28
States / cities
Beverly Hills, California • La Jolla, California • Lincoln, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 1, 2026, 9:32 AM EDT
Terminated Phase 3 Interventional Results available

Coenzyme Q10 in Huntington's Disease (HD)

NCT00608881
View directory record Official record
Conditions
Huntington's Disease
Interventions
coenzyme Q10, placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Oct 1, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional

RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer

NCT02161419
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Roniciclib (BAY1000394), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Boca Raton, Florida • Port Saint Lucie, Florida • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 1, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

NCT01056965
View directory record Official record
Conditions
Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome, Progressive Nonfluent Aphasia
Interventions
davunetide (AL-108, NAP), Placebo nasal spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 1, 2026, 9:32 AM EDT
Terminated Not applicable Interventional

The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis

NCT02078375
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Protein, Carbohydrate (Placebo), Resistance Exercise Program
Dietary Supplement · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years to 95 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 1, 2026, 9:32 AM EDT
Recruiting Phase 3 Interventional

SMART Exercise for PAD

NCT06032065
View directory record Official record
Conditions
Peripheral Arterial Disease, Aging, Peripheral Vascular Diseases, Walking, Difficulty
Interventions
Supervised Treadmill Exercise, Home-Based Exercise, Nitrate-rich beetroot Juice
Behavioral · Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 1, 2026, 9:32 AM EDT